Loading...
•
Mar 31, 2023
10X Genomics Q1 2023 Earnings Report
Reported a solid start to the year, driven by spatial portfolio performance and double-digit growth in single cell consumables.
Key Takeaways
10x Genomics reported a 17% increase in revenue for the first quarter of 2023, reaching $134.3 million. The growth was primarily driven by higher revenue in the Americas and EMEA regions, with spatial revenue growth accelerating due to strong demand for Xenium and Visium CytAssist.
Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022.
Surpassed 5,000 customer publications using 10x Genomics products.
Accelerated Spatial revenue growth driven by robust demand for Xenium and Visium CytAssist.
Opened a new R&D and manufacturing center to support the Company's innovation engine and add operational scale and capacity for future growth.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $590 million to $610 million, representing 14% to 18% growth over full year 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...